| Schedule of Segment Information |
The
following tables present the Company’s segment information for the 13 weeks ended March 28, 2026 and March 29, 2025 (in $000’s):
Schedule
of Segment Information
| | |
March
28, 2026 | | |
March
39, 2025 | |
| | |
Thirteen
Weeks Ended | |
| | |
March
28, 2026 | | |
March
29, 2025 | |
| Revenues | |
| | | |
| | |
| Fintech | |
$ | 4,712 | | |
$ | 4,849 | |
| Biotech
(Discontinued operations) | |
| — | | |
| — | |
| Corporate
and other | |
| — | | |
| — | |
| Total
Revenues | |
$ | 4,712 | | |
$ | 4,849 | |
| Gross
profit | |
| | | |
| | |
| Fintech | |
$ | 3,574 | | |
$ | 1,926 | |
| Biotech
(Discontinued operations) | |
| — | | |
| — | |
| Corporate
and other | |
| — | | |
| — | |
| Total
Gross profit | |
$ | 3,574 | | |
$ | 1,926 | |
| Operating
loss | |
| | | |
| | |
| Fintech | |
$ | (1,638 | ) | |
$ | (138 | ) |
| Biotech
(Discontinued operations) | |
| (177 | ) | |
| (540 | ) |
| Corporate
and other | |
| (1,105 | ) | |
| (1,268 | ) |
| Total
Operating loss | |
$ | (2,920 | ) | |
$ | (1,946 | ) |
| Depreciation
and amortization | |
| | | |
| | |
| Fintech | |
$ | 888 | | |
$ | 728 | |
| Biotech
(Discontinued operations) | |
| — | | |
| 482 | |
| Corporate
and other | |
| — | | |
| — | |
| Total
Depreciation and amortization | |
$ | 888 | | |
$ | 1,210 | |
| Interest
(expense) income, net | |
| | | |
| | |
| Fintech | |
$ | (379 | ) | |
$ | (376 | ) |
| Biotech
(Discontinued operations) | |
| — | | |
| — | |
| Corporate
and other | |
| (127 | ) | |
| (344 | ) |
| Total
Interest (expense) income, net | |
$ | (506 | ) | |
$ | (720 | ) |
| Net
income (loss) before income taxes | |
| | | |
| | |
| Corporate
and other | |
| (358,028 | ) | |
| (1,690 | ) |
| Total
Net income (loss) before income taxes | |
$ | (356,574 | ) | |
$ | (1,687 | ) |
|